Viridian Therapeutics, Inc.\DE 8-K

What Happened

• On May 5, 2026 Viridian Therapeutics, Inc. (VRDN) filed a Form 8-K reporting that it issued a press release announcing topline data from its Phase 3 REVEAL-2 trial of elegrobart, a subcutaneously delivered anti‑IGF‑1R antibody, in patients with chronic thyroid eye disease.
• The company also began using an updated corporate presentation that includes the REVEAL-2 topline data. The press release and presentation are furnished as Exhibits 99.1 and 99.2 to the Form 8‑K.

Key Details

• Date of filing and disclosure: May 5, 2026.
• Drug/indication: elegrobart (anti‑IGF‑1R antibody), subcutaneous delivery, for chronic thyroid eye disease.
• Trial: Phase 3, referred to as REVEAL-2; topline data announced (detailed results not recited in the 8‑K narrative).
• Materials: Press release and updated corporate presentation were attached as Exhibits 99.1 and 99.2.

Why It Matters

• A Phase 3 topline readout is a major clinical milestone that can affect Viridian’s regulatory path, development timeline, and commercial prospects for elegrobart.
• Investors should review the furnished press release and corporate presentation for efficacy, safety, and next‑step details (regulatory plans, full data releases, or timing of additional disclosures). The 8‑K itself reports the announcement but does not include full trial data or outcomes beyond the topline disclosure.